Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Blood Advances
|
August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials
Maria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
The Lancet. Oncology
|
July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vania Hungria, Paweł Robak, Marek Hus, et al.
The Lancet. Oncology
|
May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
The New England Journal of Medicine
|
June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Vania Hungria, Pawel Robak, Marek Hus, et al.
Nature Medicine
|
December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.
The New England Journal of Medicine
|
December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
The New England Journal of Medicine
|
March 27, 2020
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
M Domenica Cappellini, Vip Viprakasit, Ali T Taher, et al.
Blood
|
January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
Future Oncology (London, England)
|
September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
The New England Journal of Medicine
|
June 5, 2023
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
Jesús San-Miguel, Binod Dhakal, Kwee Yong, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Blood Advances
|
August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials
Maria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
The Lancet. Oncology
|
July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vania Hungria, Paweł Robak, Marek Hus, et al.
The Lancet. Oncology
|
May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
The New England Journal of Medicine
|
June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Vania Hungria, Pawel Robak, Marek Hus, et al.
Nature Medicine
|
December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.
The New England Journal of Medicine
|
December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
The New England Journal of Medicine
|
March 27, 2020
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
M Domenica Cappellini, Vip Viprakasit, Ali T Taher, et al.
Blood
|
January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
Future Oncology (London, England)
|
September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
The New England Journal of Medicine
|
June 5, 2023
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
Jesús San-Miguel, Binod Dhakal, Kwee Yong, et al.
Page
of 9